Search DubaiPRNetwork.com

Home >> Banking & Investments

PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine Candidate

Tuesday, October 27, 2020/ Editor -  

Share

Home >> Banking & Investments

A Philip Morris International subsidiary is a shareholder in a biopharmaceutical company that reached agreements with two departments of the Canadian government to accelerate its COVID-19 vaccine candidate efforts


United Arab Emirates -  October 27, 2020:    LAUSANNE, Switzerland--Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago’s innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI’s own efforts to leverage science and innovation. Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) is the majority shareholder and PMIBV’s partner in Medicago. Among other things, PMIBV and MTPC will contribute additional funding to support Medicago’s efforts to develop a COVID-19 vaccine candidate.


Medicago, a biopharmaceutical company headquartered in Quebec City, announced that it reached an agreement with Public Services and Procurement Canada (PSPC) to supply up to 76 million doses of its vaccine candidate for COVID-19, subject to Health Canada approval. Innovation, Science & Economic Development (ISED), another department of the Canadian federal government, will contribute C$173M (or approximately $131M) to Medicago to support its on-going vaccine development and clinical trials, and for the construction of its Quebec City manufacturing facility.


PMI’s CEO André Calantzopoulos said: “We welcome the collaboration announced between two departments of the Canadian government and Medicago to accelerate its efforts against COVID-19. Better outcomes can be achieved when governments and companies join efforts to promote shared objectives for the greater good. We are pleased to be able to support Medicago’s work to develop, substantiate, manufacture, and make available a COVID-19 vaccine candidate. We all hope they will be successful.”


Medicago began Phase 1 testing on volunteers on July 14 and is anticipating that Phase 2 trials will begin in early November 2020. If Phase 2 trials are successful, Phase 3 trials are expected to begin in December 2020.

 

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. 


Previous in Banking & Investments

Next in Banking & Investments


Home >> Banking & Investments Section

Latest Press Release

Dombrowski Takes Emphatic Solo Victory at Giro D'italia

Winner Announcement for 2021 International Prize for Arabic Fiction

Persil Abaya Shampoo Supports the Community in the GCC, Donates Abayas to the Ne ...

Celebrate with the New AIGNER EID Collection

Celebrate This Eid Al Fitr in the Coolest Theme Park With Cool Characters, Thril ...

Everyday Is MONDAY!

Aster DM Healthcare announces Global Nursing Award worth US $ 250,000

Dubai Municipality is all set to receive Eid Al Fitr

Dubai Municipality Strengthens Community Awareness on Reducing Waste Production

Celebrate this Eid with Union Coop: Two Exclusive Campaigns to make Consumers Ha ...

Your Guide to Flawless Brows this Eid with Benefit Cosmetics!

20 Years of Modern Driving Pleasure in the Mini

Emirates Literature Foundation's Kateb Maktub Team named Wikimedians of UAE User ...

Latest Sony Products in the UAE up for Grabs for Eid 2021

Samsung's Vision of the Future Home Experience Comes to Life with Bespoke

Department of Municipalities and Transport in cooperation with Modon deliver sev ...

20 Percent Off Denny's On Demand This Eid

DHA Announces Timings of Healthcare Facilities during the Eid Break

Emaar Malls Reports AED 901 Million (US$ 245 Million) in Revenue for Q1 2021

Western Furniture's Tips and Tricks for Eid Décor